By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that its second-quarter revenues increased to $800,000 from $225,000, which the firm attributed to initial fees and research revenues from certain collaborations.

The Tel Aviv, Israel-based drug discovery informatics and drug development firm posted a net loss of $896,000, or $.03 per share, for the three-month period ended June 30, compared to a profit of $2.4 million, or $.08 per share for Q2 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.